GeoVax Labs, Inc. · NASDAQ:GOVX

GeoVax Labs — Bio CEO Investor Conference 2022

24 slides from GeoVax Labs's conference presentation, Feb 14, 2022

  1. Slide 1: GeoVax, Inc.

    GeoVax, Inc. February 14-17, 2022 NASDAQ: GOVX

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstanc

  3. Slide 3: About GeoVax Labs, Inc.

    About GeoVax Labs, Inc. GeoVax Labs, Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines against a wide range of infectious diseases and cancers using three novel, proprietary platforms: GV-MVA-VLP, sMVA and GDEPT The development pipeline includes vaccines and immu

  4. Slide 4: Consolidated Balance Sheet Information

    GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) Sep 30, Dec 31, 2021 2020 Assets Cash and cash equivalents $ 18,107 $ 9,884 Other current assets 53 351 Total current assets 18,160 10,235 Property and other assets, net 180 159 Total assets $ 1

  5. Slide 5: GeoVax Announces $10 Million Private Placement

    GeoVax Announces $10 Million Private Placement ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single instit

  6. Slide 6: Pipeline Focused on Near-term Value Drivers

    Pipeline Focused on Near-term Status Funding Value Drivers Coronavirus COVID-19 (Immunocompromised patients) GEO-CM04S1 Phase 2 Internal COVID-19 (Booster to mRNA) GEO-CM04S1 Phase 2 Internal Pan Coronavirus GEO-CM02 IND-Enabling Internal & Non-Dilutive Immuno-Oncology Solid Tumors (Head & Neck)* Ge

  7. Slide 7: Infectious Disease Portfolio

    Infectious Disease Portfolio 7

  8. Slide 8: GeoVax Infectious Diseases Portfolio Jan 2021 vs. Jan 2022

    GeoVax Infectious Diseases Portfolio Jan 2021 vs. Jan 2022 SARS CoV-2 Universal “Pan” Coronavirus SARS CoV-2 Universal “Pan” Coronavirus 1. Lead candidate identified - GEO-CM02 2. Preclinical testing advanced, single dose protection from variants 1. MVA-VLP based 3. Expanded research relationships u

  9. Slide 9: Phase 2 Trial – Immunocompromised Patients

    9 Covid-19 Vaccine (GEO-CM04S1) Phase 2 Trial – Immunocompromised Patients ▪ Diminished antibody responses compared to healthy vaccinated individuals have been shown in immunocompromised patients provided mRNA COVID-19 vaccines ▪ A COVID-19 vaccine which favors broader induction of cellular immune r

  10. Slide 10: Phase 2 Trial – Booster vaccination to mRNA vaccines

    0 Covid-19 Vaccine (GEO-CM04S1) Phase 2 Trial – Booster vaccination to mRNA vaccines ▪ Governments have started recommending 3rd doses of currently authorized COVID-19 vaccines ▪ In the US high risk subjects are eligible for a booster if they received Pfizer/Moderna vaccines. All individuals who hav

  11. Slide 11: GEO-CM02 Universal Coronavirus Vaccine Results to Date

    GEO-CM02 Universal Coronavirus Vaccine Results to Date • The use of MVA as a vector supports the design and production of “next- gen” vaccines encoding multiple viral proteins • S protein as the antibody target • M and E as T-cell targets • The combination of S, M and E protein expression supports V

  12. Slide 12: GEO-CM02 & GEO-CM04S1: Synergies

    GEO-CM02 & GEO-CM04S1: Synergies • The use of MVA as a vaccine vector is the core technology of GeoVax • Experimental products for use against a diverse set of infectious diseases in different stages of preclinical and clinical development • Funding partnerships with multiple US government agencies

  13. Slide 13: Immuno-oncology Portfolio

    Immuno-oncology Portfolio 13

  14. Slide 14: GeoVax Immuno-Oncology Portfolio Jan 2021 vs. Jan 2022

    GeoVax Immuno-Oncology Portfolio Jan 2021 vs. Jan 2022 MUC1 Solid tumors MUC1 Solid tumors 1. Clinical candidate selected 1. MVA-VLP based, experimental 2. GMP manufacturing initiated 2. Preclinical 3. Research and clinical testing relationships under final negotiation 3. Internal funding 4. Assembl

  15. Slide 15: Chemotherapy and Radiation Treatments Frequently Fail

    Chemotherapy and Radiation Treatments Frequently Fail ▪ These modalities fail to treat the large numbers of silent, quiescent cells in a tumor mass. ▪ The GDEPT (Gene-Directed Enzyme Prodrug Therapy) technology is specifically designed to destroy these cells. 15

  16. Slide 16: Mechanism of Action e.g., Gedeptin

    Mechanism of Action e.g., Gedeptin® F-araAMP (Fludara, Fludarabine phosphate) Gedeptin® (Ad/PNP) Plasma enzymes F-araA (Fludarabine) E. coli PNP in tumor cells Fluoroadenine Unprecedented level of cell killing activity Novel tumor killing mechanism Destroys refractory solid tumors 16

  17. Slide 17: Approved Phase II Clinical Protocol

    Approved Phase II Clinical Protocol ▪ Utilizes dose and schedule found safe and effective in Phase I/IIa trial (as a single cycle*) ▪ Up to 5 cycles will be administered ▪ The entire tumor burden will be treated * Two days of Gedeptin followed by 3 days of fludarabine 17

  18. Slide 18: Potential Path to Regulatory Filing for FDA Approval

    Potential Path to Regulatory Filing for FDA Approval ▪ Expanded enrollment completed: YE 2022 ▪ Completion of patient evaluations: YE 2023 ▪ BLA filing: H1 2024 18

  19. Slide 19: Gedeptin Improves efficacy of check point blockade inhibitors

    Gedeptin® Improves efficacy of check point blockade inhibitors Recent studies indicate that Gedeptin® treatment is additive or synergistic with checkpoint blockade type agents. Gedeptin® therapy robustly sensitizes tumors that do not express E. coli PNP to checkpoint blockade inhibitors, presumably

  20. Slide 20: GeoVax Novel Concept to Cancer Immunotherapy

    GeoVax Novel Concept to Cancer Immunotherapy Triple-threat Approach: 1 Stimulate tumor specific 2 Augment immune responses 3 Immune inhibition is blocked with checkpoint responses utilizing MVA- using homologous peptide VLP technology vaccine inhibitors STIMULATE: MVA-VLP with TAA to provoke immune

  21. Slide 21: GeoVax MVA-VLP-MUC1 – Promising Results

    GeoVax MVA-VLP-MUC1 – Promising Results Therapeutic Experiment Results Prevention “Recurrence” Experiment Results MVA-VLP-MUC1 + Peptide 1.0 No Treatment Tumor Progression Tumor Growth (cm) 500 400 Tumor Weight (mg) Untreated 0.5 300 Anti-mPD-1 alone (MVA+ MTI) + Anti-mPD-1 200 MTI+ Anti-mPD-1 (4 do

  22. Slide 22: Strong IP for GeoVax Technology

    Strong IP for GeoVax Technology Our patent portfolio covers >70 granted or pending patent • COVID-19 vaccines • Immuno-oncology • Hemorrhagic fever (Ebola, Marburg, Sudan, Lassa) applications spread over • Zika, Malaria vaccine 20 patent families • HIV • HPV-associated cancer • Hepatitis B vaccine 2

  23. Slide 23: Pipeline Focused on Near-term Value Drivers

    Pipeline Focused on Near-term Status Funding Value Drivers Coronavirus COVID-19 (Immunocompromised patients) GEO-CM04S1 Phase 2 Internal COVID-19 (Booster to mRNA) GEO-CM04S1 Phase 2 Internal Pan Coronavirus GEO-CM02 IND-Enabling Internal & Non-Dilutive Immuno-Oncology Solid Tumors (Head & Neck)* Ge

  24. Slide 24: Thank You

    Thank You Creating Vaccines to Serve Humanity For More Information GeoVax Labs, Inc. investor@geovax.com 678-384-7220 1900 Lake Park Drive, Suite 380 Atlanta, GA 30080 Tel: (678) 384-7220 Fax: (678) 384-7281 www. geovax.com NASDAQ: GOVX

GeoVax Labs — Bio CEO Investor Conference 2022 on 6ix